Olfactomedin 4 produces dysplasia but suppresses metastasis of colon cancer

Hyun Woo Ma; Jung Min Kim; Da Hye Kim; I. Seul Park; Ji Hyung Kim; Ki Cheong Park; Dong Hyuk Seo; Jae Hyeon Kim; Xiumei Che; Tae Il Kim; Jae Hee Cheon; Seung Won Kim

doi:10.1038/s41417-022-00585-9

Olfactomedin 4 produces dysplasia but suppresses metastasis of colon cancer

Hyun Woo Ma, Jung Min Kim, Da Hye Kim, I. Seul Park, Ji Hyung Kim, Ki Cheong Park, Dong Hyuk Seo, Jae Hyeon Kim, Xiumei Che, Tae Il Kim, Jae Hee Cheon, Seung Won Kim

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Development of colorectal cancer (CRC) is regulated by a series of genetic and microenvironmental alterations. Olfactomedin 4 (OLFM4) is a secreted glycoprotein that is highly expressed in the gastrointestinal tract and modulates inflammation. However, the role of OLFM4 in CRC is uncertain. Here we aimed to explore the function of OLFM4 in CRC in vivo and in vitro. The mRNA expression of OLFM4 was up-regulated in precursor lesions with dysplasia or ulcerative colitis but was reduced in CRC. OLFM4 neutralizing antibody suppressed inflammation-mediated early-stage CRC formation in an AOM/DSS colitis-associated cancer model. OLFM4 knockdown cells exhibited increased cell proliferation and motility in vitro and in vivo. Ablation of OLFM4 increased tumor growth and metastasis in xenograft experiments. In addition, OLFM4 knockdown cells showed elevated expression of colon cancer stem cell markers including CD133, resulting in increased metastasis via epithelial-mesenchymal transition signaling. This study demonstrated that OLFM4 regulates inflammation and cancer progression differently; ablation of OLFM4 promotes cancer metastasis via stemness and epithelial-mesenchymal transition. These results suggest a new route for controlling cancer progression and metastasis.

Original language	English
Journal	Cancer Gene Therapy
DOIs	https://doi.org/10.1038/s41417-022-00585-9
Publication status	Accepted/In press - 2022

Bibliographical note

Funding Information:
This work was supported by the Korean Gastroenterology Fund for Future Development and by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF-2020R1A2C1005322). We would like to thank the donors for their contribution to this study.

Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature America, Inc.

All Science Journal Classification (ASJC) codes

Molecular Medicine
Molecular Biology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41417-022-00585-9

Cite this

@article{3cb9c83a9ef1422186c1bc1659437a07,

title = "Olfactomedin 4 produces dysplasia but suppresses metastasis of colon cancer",

abstract = "Development of colorectal cancer (CRC) is regulated by a series of genetic and microenvironmental alterations. Olfactomedin 4 (OLFM4) is a secreted glycoprotein that is highly expressed in the gastrointestinal tract and modulates inflammation. However, the role of OLFM4 in CRC is uncertain. Here we aimed to explore the function of OLFM4 in CRC in vivo and in vitro. The mRNA expression of OLFM4 was up-regulated in precursor lesions with dysplasia or ulcerative colitis but was reduced in CRC. OLFM4 neutralizing antibody suppressed inflammation-mediated early-stage CRC formation in an AOM/DSS colitis-associated cancer model. OLFM4 knockdown cells exhibited increased cell proliferation and motility in vitro and in vivo. Ablation of OLFM4 increased tumor growth and metastasis in xenograft experiments. In addition, OLFM4 knockdown cells showed elevated expression of colon cancer stem cell markers including CD133, resulting in increased metastasis via epithelial-mesenchymal transition signaling. This study demonstrated that OLFM4 regulates inflammation and cancer progression differently; ablation of OLFM4 promotes cancer metastasis via stemness and epithelial-mesenchymal transition. These results suggest a new route for controlling cancer progression and metastasis.",

author = "Ma, {Hyun Woo} and Kim, {Jung Min} and Kim, {Da Hye} and Park, {I. Seul} and Kim, {Ji Hyung} and Park, {Ki Cheong} and Seo, {Dong Hyuk} and Kim, {Jae Hyeon} and Xiumei Che and Kim, {Tae Il} and Cheon, {Jae Hee} and Kim, {Seung Won}",

note = "Funding Information: This work was supported by the Korean Gastroenterology Fund for Future Development and by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF-2020R1A2C1005322). We would like to thank the donors for their contribution to this study. Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Nature America, Inc.",

year = "2022",

doi = "10.1038/s41417-022-00585-9",

language = "English",

journal = "Cancer Gene Therapy",

issn = "0929-1903",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Olfactomedin 4 produces dysplasia but suppresses metastasis of colon cancer

AU - Ma, Hyun Woo

AU - Kim, Jung Min

AU - Kim, Da Hye

AU - Park, I. Seul

AU - Kim, Ji Hyung

AU - Park, Ki Cheong

AU - Seo, Dong Hyuk

AU - Kim, Jae Hyeon

AU - Che, Xiumei

AU - Kim, Tae Il

AU - Cheon, Jae Hee

AU - Kim, Seung Won

N1 - Funding Information: This work was supported by the Korean Gastroenterology Fund for Future Development and by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF-2020R1A2C1005322). We would like to thank the donors for their contribution to this study. Publisher Copyright: © 2022, The Author(s), under exclusive licence to Springer Nature America, Inc.

PY - 2022

Y1 - 2022

N2 - Development of colorectal cancer (CRC) is regulated by a series of genetic and microenvironmental alterations. Olfactomedin 4 (OLFM4) is a secreted glycoprotein that is highly expressed in the gastrointestinal tract and modulates inflammation. However, the role of OLFM4 in CRC is uncertain. Here we aimed to explore the function of OLFM4 in CRC in vivo and in vitro. The mRNA expression of OLFM4 was up-regulated in precursor lesions with dysplasia or ulcerative colitis but was reduced in CRC. OLFM4 neutralizing antibody suppressed inflammation-mediated early-stage CRC formation in an AOM/DSS colitis-associated cancer model. OLFM4 knockdown cells exhibited increased cell proliferation and motility in vitro and in vivo. Ablation of OLFM4 increased tumor growth and metastasis in xenograft experiments. In addition, OLFM4 knockdown cells showed elevated expression of colon cancer stem cell markers including CD133, resulting in increased metastasis via epithelial-mesenchymal transition signaling. This study demonstrated that OLFM4 regulates inflammation and cancer progression differently; ablation of OLFM4 promotes cancer metastasis via stemness and epithelial-mesenchymal transition. These results suggest a new route for controlling cancer progression and metastasis.

AB - Development of colorectal cancer (CRC) is regulated by a series of genetic and microenvironmental alterations. Olfactomedin 4 (OLFM4) is a secreted glycoprotein that is highly expressed in the gastrointestinal tract and modulates inflammation. However, the role of OLFM4 in CRC is uncertain. Here we aimed to explore the function of OLFM4 in CRC in vivo and in vitro. The mRNA expression of OLFM4 was up-regulated in precursor lesions with dysplasia or ulcerative colitis but was reduced in CRC. OLFM4 neutralizing antibody suppressed inflammation-mediated early-stage CRC formation in an AOM/DSS colitis-associated cancer model. OLFM4 knockdown cells exhibited increased cell proliferation and motility in vitro and in vivo. Ablation of OLFM4 increased tumor growth and metastasis in xenograft experiments. In addition, OLFM4 knockdown cells showed elevated expression of colon cancer stem cell markers including CD133, resulting in increased metastasis via epithelial-mesenchymal transition signaling. This study demonstrated that OLFM4 regulates inflammation and cancer progression differently; ablation of OLFM4 promotes cancer metastasis via stemness and epithelial-mesenchymal transition. These results suggest a new route for controlling cancer progression and metastasis.

UR - http://www.scopus.com/inward/record.url?scp=85145036610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85145036610&partnerID=8YFLogxK

U2 - 10.1038/s41417-022-00585-9

DO - 10.1038/s41417-022-00585-9

M3 - Article

C2 - 36577836

AN - SCOPUS:85145036610

SN - 0929-1903

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

ER -

Olfactomedin 4 produces dysplasia but suppresses metastasis of colon cancer

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this